Molecular Docking Analysis of Eugenol and Paclitaxel Targeting MRAS in Breast Cancer Therapy

Breast cancer is the leading cause of cancer-related deaths among women globally, with its incidence rising worldwide. MRAS, which has unique functions related to classical RAS oncoproteins, is significantly more expressed in estrogen receptor-negative than in estrogen receptor-positive breast carcinomas and is crucial for cell migration and differentiation, influencing cell polarity and prompting research into potential treatments. Eugenol has antioxidant and anti-inflammatory effects, and it can induce apoptosis in cancer cells while inhibiting their migration and viability through specific pathways. Additionally, paclitaxel, a taxane chemotherapy agent, is a vital treatment for breast cancer, disrupting microtubule dynamics to stop cell division and induce apoptosis, significantly improving survival rates and reducing cancer recurrence risk. The aim of this study is to investigate the molecular interactions of eugenol and paclitaxel with the MRAS protein through protein docking, assessing their binding energies. This study will evaluate how these two compounds bind to and block the MRAS protein, which subsequently has inhibitory effects on downstream pathways.

کلیدواژه ها:

Breast cancer ، MRAS protein ، Eugenol ، Paclitaxel ، Molecular docking ، Apoptosis ، Cell migration ، Chemotherapy